OXB is a specialist gene and cell therapy viral-vector biopharmaceutical company. It offers vector manufacturing and development services, whilst retaining its own proprietary therapeutic candidates. Above service-fees, OXB will receive royalties on commercial products developed with its LentiVector® platform. OXB has made two significant announcements during the past week which reduce risk and greatly improve sentiment towards the stock. First, refinancing of its existing loan with a new, more favourable debt facility from Oakland Capital. Secondly, a deal with Novartis to supply vector for use in the manufacture of certain CAR-T therapies.
07 Jul 2017
Major deal to supply Novartis CAR-T programmes
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Major deal to supply Novartis CAR-T programmes
Oxford BioMedica plc (OXB:LON) | 202 -4.1 (-1.0%) | Mkt Cap: 202.5m
- Published:
07 Jul 2017 -
Author:
Martin Hall -
Pages:
12
OXB is a specialist gene and cell therapy viral-vector biopharmaceutical company. It offers vector manufacturing and development services, whilst retaining its own proprietary therapeutic candidates. Above service-fees, OXB will receive royalties on commercial products developed with its LentiVector® platform. OXB has made two significant announcements during the past week which reduce risk and greatly improve sentiment towards the stock. First, refinancing of its existing loan with a new, more favourable debt facility from Oakland Capital. Secondly, a deal with Novartis to supply vector for use in the manufacture of certain CAR-T therapies.